59 results on '"Pacchetti, C"'
Search Results
2. Does Deep Brain Stimulation worsen cognitive decline in GBA-Parkinson Disease patients? A longitudinal study of the Italian PARKNET cohort
3. A case report of acute thrombocytopenia induced by Apomorphine in a patient with Parkinson's disease with motor fluctuations
4. Correction to: Gender differences in microRNA expression in levodopa‑naive PD patients
5. Gender differences in microRNA expression in levodopa-naive PD patients
6. Cognitive disorders in normal pressure hydrocephalus with initial parkinsonism in comparison with de novo Parkinson's disease
7. Specific patterns of laryngeal electromyography during wakefulness are associated to sleep disordered breathing and nocturnal stridor in multiple system atrophy
8. SUN-P199: Double-Blind, Placebo-Controlled Trial of a Fermented Milk Containing Multiple Probiotic Strains and Prebiotic Fiber for Constipation Associated with Parkinson's Disease
9. Double blind, placebo-controlled trial of a fermented milk containing multiple probiotics strains and prebiotic fiber for constipation associated with parkinson’s disease
10. Aging brain and dementia: change in central opioids and ACTH
11. Subthalamic involvement in monetary reward and its dysfunction in parkinsonian gamblers
12. Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens
13. Transcranial direct current stimulation for treatment of freezing of gait in Parkinson's disease. A cross-over study
14. Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care
15. 15 Mild Cognitive Impairment in Parkinson’s disease
16. 22 GPi Deep Brain Stimulation after STN DBS: Cases report
17. 2.306 WHAT THE SUBTHALAMIC LOCAL FIELD POTENTIALS SAY AFTER YEARS OF CHRONIC STIMULATION IN PARKINSON'S DISEASE?
18. 2.304 THE DYNAMIC OF SUBTHALAMIC LOW FREQUENCY OSCILLATIONS AFTER LEVODOPA INTAKE AND DURING ONGOING DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE
19. 2.256 SYMPTOMATIC NEUROPATHY IN PARKINSON'S DISEASE PATIENTS DURING DUODENAL LEVODOPA INFUSION TREATMENT
20. Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease
21. P23.19 Facilitated temporal summation of pain at spinal level in multiple system atrophy
22. How parkinsonism influences life: the patients’ point of view
23. Duodenal Levodopa Infusion Improves Quality of Life in Advanced Parkinson’s Disease
24. Homocysteine and Parkinson's disease: A dangerous liaison?
25. Electrophysiologic patterns of oral-pharyngeal swallowing in parkinsonian syndromes
26. Sleep disorders in Parkinson's disease: facts and new perspectives
27. 2.220 Duodenal levodopa infusion for advanced Parkinson's disease: 24-month treatment outcome
28. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease
29. Neuroleptic Treatment and Extrapyramidal Disorders: A Survey In Long-Term Institutionalized Psychiatric Patients In Italy
30. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot
31. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson?s disease. The effect of dopaminergic treatment
32. COGNITIVE REHABILITATION IN PARKINSON’S DISEASE
33. Sleep attacks in Parkinson?s disease: a clinical and polysomnographic study
34. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson?s disease
35. Hallucinations and sleep-wake cycle in PD: A 24-hour continuous polysomnographic study
36. Parkinson's disease and reproductive life events
37. Not paralysis, but dystonia causes stridor in multiple system atrophy
38. Botulinum toxin treatment for functional disability induced by essential tremor
39. Peripheral markers of oxidative stress in Parkinson’s disease. the role of L-DOPA
40. Is seborrhea a sign of autonomic impairment in Parkinson's disease?
41. Simultaneous determination of l-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection
42. Pituitary-adrenal responses to dexamethasone and CRH administration in patients with untreated Parkinson’s disease
43. ?Off? painful dystonia in Parkinson's disease treated with botulinum toxin
44. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease
45. Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study
46. Masseteric reflex excitability curve following conditioning exteroceptive stimuli in primary cranial dystonias
47. Changes in motoneuron excitability of masseter muscle following exteroceptive stimuli in Parkinson's disease
48. Reaction time responses in parkinsonian and hemiparkinsonian patients
49. IS TOLOSA—HUNT SYNDROME A LIMITED FORM OF WEGENER'S GRANULOMATOSIS? REPORT OF TWO CASES WITH ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES
50. Nocturnal sleep in multisystem atrophy with autonomic failure: polygraphic findings in ten patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.